Navigation Links
The pill for ovarian cysts
Date:3/30/2010

Ovarian endometriomas, better known as ovarian 'chocolate' cysts for the brown liquid they contain, can be easily removed by surgery. However, recurrence is common, which can cause ongoing pain and complications. A study evaluated for Faculty of 1000 suggests a simple and effective remedy the oral contraceptive pill (OCP).

In their F1000 evaluation, Neil Johnson and Shelley Reilly from Auckland, New Zealand, highlight a trial published in Fertility and Sterility that provides evidence that the OCP can reduce the reoccurrence of endometriomas after removal by surgery. They say, "this study is perhaps the only randomized controlled trial that has evaluated the effectiveness of the use of long-term postoperative OCP treatment to prevent endometrioma recurrence."

The trial consisted of 239 patients who had just undergone surgery to remove endometriomas and who were randomized into groups: those with no prescribed treatment, those taking cyclic OCPs, and those taking continuous OCPs. Patients were followed up for two years.

Women who took OCPs had significantly fewer recurring cysts. Previous studies of the effectiveness of OCPs after laparoscopic cystectomy have produced conflicting results. But long-term treatment seems to be the key: Johnson and Reilly say, "the length of treatment appears to play an important role in the efficacy of therapy".

Johnson and Reilly suggest an immediate change to current clinical practice: "If the use of an OCP is considered to reduce the risk of recurrence of an endometrioma after laparoscopic cystectomy, treatment should be given for at least two years".


'/>"/>

Contact: Constantine Stamatopoulos
press@f1000.com
Faculty of 1000: Biology and Medicine
Source:Eurekalert

Page: 1

Related biology news :

1. Dietary factors influence ovarian cancer survival rates
2. Disarming specialized stem cells might combat deadly ovarian cancer
3. Assessing lead time of selected ovarian cancer biomarkers
4. FDA approved leukemia drugs shows promise in ovarian cancer cells
5. Nanoparticle-delivered suicide genes slowed ovarian tumor growth
6. 2 reproductive factors are important predictors of death from ovarian cancer
7. Genetic factors implicated in survival gap for breast, ovarian or prostate cancer
8. Ovarian transplantation: First baby is born after a new technique
9. Ovarian transplantation: New technique gives greatly improved results in this delicate operation
10. Genetic testing for breast or ovarian cancer risk may be greatly underutilized
11. Promising new treatment option for women with recurrent ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology: